AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

AstraZeneca is backing up its considerable investment in antibody-drug conjugates (ADCs) for cancer with the construction of a $1.5 billion new facility in Singapore to manufacture them.